Sleeping pill ad war heats up after Ambien concerns
Sanofi Aventis launched a new Ambien campaign amid sales declines tied to sleepwalking side effects. Analysts forecast a fierce advertising battle as Pfizer and Neurocrine plan a competing pill, indiplon, with Lunesta also contending. Prescriptions fell for Ambien and rivals as safety worries persist.
MENTIONED IN THIS ARTICLE
New York
Ambien
Sanofi-Aventis SA
Sanofi
Pfizerinc
Neurocrine Sciences Inc
Erec
Jason Napodano
Zacks Independent Research
Pfizer
Indiplon
Lunesta
Sepracar Inc
IMS Health
Ambien CA
Verispan
Linesta’s
Ambien Ci’s
Ambien CR
Limesta
Slaysia Weiber
Mount Sinai Hospital
Fimothy Romoto
Minneapolis
Ous
Sanofi-Aventis
Melisa Feltmann
Lunesia
Sepreen
First human tests show bird flu vaccine only modestly effective
The first human trial of the bird flu vaccine shows a protective response in 54 percent of high-dose recipients, with 28 day spacing. Regular flu shots protect 75–80 percent in the same group. Researchers are testing a third dose and immune-boosting additives while stockpiled supply covers about four million people.
MENTIONED IN THIS ARTICLE
Washington
New England Journal of Medicine
John Treanor
University of Rochester
Anthony Fauci
National Institutes of Health
Fauci
Mayo Clinic Hu
Gregory Poland
William Schaffner
Vanderbilt University
Also Mentioned on This Page
valueCity
Elasionics
City Furniture
V. Plus
Dinae
Lengel
Costinare
Ente
Entire Stock Children's
Elyria
Oberlin Rd
Euclid
Shore
Parma
Brookpark
Warrensville
Miles
Lauren Neergaard